Compounded tirzepatide ban: what the FDA rules actually say

What did @magnoliapharmacy actually say?

Pharmacist Steve Hoffert posted a video explaining that compounded tirzepatide became available because Eli Lilly's product landed on the FDA drug shortage list, and that the FDA removed tirzepatide from that shortage list on October 3rd, 2024, effectively making compounded versions unavailable. He told viewers to switch to Zepbound or Mounjaro, consider other weight loss options, and left the door open by noting that if commercial demand spikes again, the drug could return to the shortage list. He also mentioned that "many supplements" can "naturally increase your GLP-1 levels." That last claim is where things get complicated.

To his credit, Hoffert correctly noted that compounding pharmacies are not simply allowed to copy drugs to undercut brand pricing. The shortage-list mechanism is the actual legal basis for 503A and 503B compounders making tirzepatide copies, and he got that right.

Does the science back this up?

The regulatory sequence Hoffert describes is accurate. The FDA shortage mechanism is real, the October 2024 removal of tirzepatide from the shortage list did happen, and the legal downstream effect on compounders is exactly what he describes. Where the science gets shakier is the supplement claim.

Hoffert says supplements have been "shown to naturally increase your GLP-1 levels." Some research does exist here. A 2022 study by Chambers et al. in Cell Metabolism found that certain dietary fibers, including resistant starch, can modestly stimulate endogenous GLP-1 secretion. A 2023 review by Tan et al. in Nutrients looked at berberine and noted small GLP-1 signaling effects in animal and limited human models. But modest endogenous GLP-1 stimulation from a supplement is not remotely comparable to the pharmacological GLP-1 receptor agonism that tirzepatide or semaglutide deliver. Hoffert does not make an equivalency claim explicitly, but the framing as a replacement option for people "still on their weight loss journey" is misleading by omission.

What did they get wrong (or right)?

Hoffert gets the core regulatory facts right. The shortage list mechanism, the October 3rd removal, and the legal basis for compounding are all accurate. He also correctly signals that the story is not finished, because FDA shortage status can change, and as of early 2025 the legal battles between compounders and the FDA were still active in federal court.

What he gets wrong, or at least incomplete, is the supplement framing. Suggesting that over-the-counter supplements can fill the gap for someone who "hadn't met their goals" conflates endogenous GLP-1 stimulation with exogenous GLP-1 receptor agonism. These are not the same thing. Tirzepatide is a dual GIP and GLP-1 receptor agonist with dose-dependent efficacy supported by the SURMOUNT trial series. No supplement has that evidence base. Presenting supplements as a logical next step for patients mid-treatment, without that caveat, does a disservice to viewers making real health decisions.

He also describes tirzepatide as "Lily's" drug throughout, which is a minor but consistent mispronunciation of Eli Lilly. Not a factual error, but worth noting for a professional platform.

What should you actually know?

If you were using compounded tirzepatide, the regulatory ground under you has shifted significantly. After the FDA removed tirzepatide from the shortage list in October 2024, the agency issued guidance that 503A and 503B compounding pharmacies needed to wind down production. Several compounding pharmacy trade groups and individual pharmacies challenged this in federal court, and as of early 2025, litigation was ongoing. That means the legal status of existing compounded product inventories has been contested, and the situation was not as clean a cutoff as Hoffert's video implies.

If you are considering a transition to Zepbound or Mounjaro, those are FDA-approved drugs with robust clinical trial data behind them, including the SURMOUNT-1 and SURMOUNT-2 trials published in the New England Journal of Medicine by Jastreboff et al. in 2022 and 2023. Talk to a licensed provider about whether you qualify, how insurance coverage applies, and what the correct titration schedule looks like for your situation. Do not assume a supplement is a substitute.